{"id":11192,"date":"2021-05-28T00:00:00","date_gmt":"2021-05-28T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/"},"modified":"2025-08-19T08:28:17","modified_gmt":"2025-08-19T13:28:17","slug":"pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/","title":{"rendered":"POMALYST (POMALIDOMIDE) ET THALOMID (THALIDOMIDE) &#8211; \u00c9VALUATION DU RISQUE POTENTIEL DE LEUCOENC\u00c9PHALOPATHIE MULTIFOCALE PROGRESSIVE"},"content":{"rendered":"<p><a href=\"\/pixms\/uploads\/serve\/ckeditor\/fr_21_106578_783_stakeholders_notification_pomalidomide_and_thalidomide_pml-2.pdf\" target=\"_blank\" rel=\"noopener\">Un r\u00e9sum\u00e9 de l\u2019examen de l\u2019innocuit\u00e9 (REI) concernant Pomalyst (pomalidomide) et Thalomid (thalidomide) et le risque potentiel de leucoenc\u00e9phalopathie multifocale progressive (LEMP) a \u00e9t\u00e9 publi\u00e9 par Sant\u00e9 Canada.<\/a> Le but du REI est de permettre \u00e0 la population canadienne d\u2019avoir une compr\u00e9hension suffisante de l\u2019examen de l\u2019innocuit\u00e9 qui a \u00e9t\u00e9 men\u00e9 par Sant\u00e9 Canada, plus pr\u00e9cis\u00e9ment, ce qui a \u00e9t\u00e9 \u00e9valu\u00e9 et constat\u00e9, ainsi que les mesures qui ont \u00e9t\u00e9 prises.&nbsp;\u00bb<\/p>\n<p><a href=\"\/pixms\/uploads\/serve\/ckeditor\/fr_ssr_pomalidomide_and_thalidomide_pml_final.pdf\" target=\"_blank\" rel=\"noopener\">Lire le r\u00e9sum\u00e9 de l\u2019examen de l\u2019innocuit\u00e9 (REI)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Un r\u00e9sum\u00e9 de l\u2019examen de l\u2019innocuit\u00e9 (REI) concernant Pomalyst (pomalidomide) et Thalomid (thalidomide) et le risque potentiel de leucoenc\u00e9phalopathie multifocale progressive (LEMP) a \u00e9t\u00e9 publi\u00e9 par Sant\u00e9 Canada. Le but du REI est de permettre \u00e0 la population canadienne d\u2019avoir une compr\u00e9hension suffisante de l\u2019examen de l\u2019innocuit\u00e9 qui a \u00e9t\u00e9 men\u00e9 par Sant\u00e9 Canada, plus [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11192","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11192"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11192\/revisions"}],"predecessor-version":[{"id":31299,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11192\/revisions\/31299"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}